Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications.
about
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetes and cancer: a consensus report.Identification of possible adverse drug reactions in clinical notes: The case of glucose-lowering medicinesLong-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes.Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.Defining and achieving treatment success in patients with type 2 diabetes mellitusIncretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitusPersonalizing guidelines for diabetes management: twilight or dawn of the expert?Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes.Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.Interpreting adverse signals in diabetes drug development programs.Changing prescribing patterns of type 2 diabetes medications from 2002-2010: an electronic health record-based evaluation.Diabetes and cardiovascular disease: what have we learned in 2012?Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes.Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes.Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.Incretin therapy for type 2 diabetes mellitus.Initial combination with linagliptin and metformin in newly diagnosed type 2 diabetes and severe hyperglycemia.Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes.Safety of antidiabetes medications: An update.Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum.Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes.Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis.Anti-diabetic medications: How to make a choice?
P2860
Q22241288-6B16FCF0-E01C-443E-AB01-56E4F08565BEQ27686977-FBEBBD4C-F88F-47F0-9338-85EABFE76893Q30002304-3A2CB7A9-C93E-41D8-94AF-8225860CDEBFQ33585566-C6CF99E2-A82F-49FF-8BC6-CD3BCE0CB899Q33602360-FC14587B-A450-48F4-90ED-CBB13C01EC53Q34374314-3E245BC2-1019-4949-A82F-9E9867A38BF3Q34374350-758412E2-FB2F-48F2-8403-C5D2D5A27AA7Q34810165-48F94A85-2D99-42D9-8DDA-B179F461429CQ35548033-814AEE97-67DF-4A7F-B8EF-6422749C9625Q36498695-D23FE2E3-A9AE-4DF9-8631-D1D9C918AB55Q36942266-30B76635-4738-44F1-8773-D9C09D4B4108Q36954288-AA09800B-FB97-4826-BFEB-A1D493EC4D41Q37005371-42B5040F-565C-4AE6-897E-F4F40B7B577BQ37239278-158B4F79-5937-4F11-A28C-9D6A51511784Q37594479-17EA00C6-D6CC-482B-B113-B18BE3CBF63BQ37772523-F9ABB9D7-B626-4CF9-9A0A-3E32E2AA80BAQ37803364-2A697C26-28F4-4248-8EC7-A9D99DFE3BDCQ38065105-822A514E-B715-4C34-8D34-12FD1489FC4CQ38167016-F3426165-EC8C-4E80-8F0F-DD72991A2B44Q38395221-821A3B4E-BB02-4A4A-9641-0DA7ABE45FC3Q39413300-836E97B0-4D4E-4A01-8F74-FE7F00BDBD60Q45231648-B6CF4C8E-9B34-4896-91AC-0920A8032406Q47149127-33710BD1-AF28-4811-B6B2-8C76377A5238Q47771118-A65255E1-DE96-4292-9A7F-E4E776A50B07Q51563502-C1416A31-44C8-46E5-BB20-4495538986BFQ53601871-C7B01494-8E9F-4CAA-BFE2-0800F5994961
P2860
Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Type 2 diabetes: assessing the ...... glucose-lowering medications.
@en
Type 2 diabetes: assessing the ...... glucose-lowering medications.
@nl
type
label
Type 2 diabetes: assessing the ...... glucose-lowering medications.
@en
Type 2 diabetes: assessing the ...... glucose-lowering medications.
@nl
prefLabel
Type 2 diabetes: assessing the ...... glucose-lowering medications.
@en
Type 2 diabetes: assessing the ...... glucose-lowering medications.
@nl
P921
P1476
Type 2 diabetes: assessing the ...... f glucose-lowering medications
@en
P2093
David M Kendall
Richard M Bergenstal
P304
374.e 9 -18
P356
10.1016/J.AMJMED.2009.07.017
P407
P577
2010-04-01T00:00:00Z